Genvion has added to its contract development and manufacturing expertise with the addition of new spray drying and Wurster coating technology. The new capabilities, bringing on-line spray dryers and Wurster coaters, follows the successful installation and validation of the advanced manufacturing equipment at its new, state-of-the-art 80,000 sq. ft facility.

Genvion’s VP, Tony Cocci said, “Customer demand for GMP spray drying is increasing because of the need to support poorly soluble drugs. This latest investment diversifies Genvion’s capability to address these demands and broadens our manufacturing services, whilst also boosting our existing high containment and cytotoxic niche expertise.”

The substantial investment, expected to be close to $1.5m when taking into account both the spray drying and Wurster equipment, is part of Genvion’s ongoing plans to expand its GMP manufacturing capabilities at its facility in Winnipeg, Canada and comes in direct response to customer demand for spray drying and drug layering from big pharma companies through to small specialty firms.